Cristina Sarrosa, APRN
Primary Care · Tulsa, OKNPI 1376097261
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 340 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 12.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,825, 2.9 times the $638 reported in 2021. Among primary care clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 340 payments — averaging $17.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$759
- Pfizer$680
- AbbVie$542
- Novo Nordisk$540
- Lilly USA, LLC$412
- GSK$408
- plus $3K from 27 others
What the payments were for
- Food & beverage$6,014100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 33 | $759 |
| Pfizer | 38 | $680 |
| AbbVie | 39 | $542 |
| Novo Nordisk | 30 | $540 |
| Lilly USA, LLC | 25 | $412 |
| GSK | 28 | $408 |
| Bayer | 21 | $364 |
| UCB, Inc. | 10 | $221 |
| Eisai Inc. | 9 | $205 |
| Boehringer Ingelheim | 11 | $190 |
| Astellas Pharma US Inc | 9 | $185 |
| Amgen | 14 | $183 |
| Exact Sciences | 9 | $152 |
| Corium, LLC | 7 | $144 |
| Sumitomo Pharma America, Inc. | 5 | $105 |
| Ardelyx, Inc. | 5 | $102 |
| Idorsia Pharmaceuticals US Inc | 5 | $97 |
| Johnson & Johnson | 5 | $80 |
| Phathom Pharmaceuticals, Inc. | 4 | $71 |
| Biogen | 3 | $71 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $70 |
| Daiichi Sankyo Inc. | 3 | $62 |
| Boston Scientific | 4 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $59 |
| Otsuka America Pharmaceutical, Inc. | 3 | $59 |
| Lundbeck LLC | 3 | $42 |
| Abbott | 2 | $35 |
| Novartis | 2 | $29 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Merck | 1 | $19 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$101
How this compares
$6,014 in reported general payments places this provider in the 95th percentile of 83 primary care providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 182 | $157,600 |
| OzempicSemaglutide | 52 | $54,421 |
| JardianceEmpagliflozin | 31 | $46,787 |
| MyrbetriqMirabegron | 68 | $38,382 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $31,539 |
| XareltoRivaroxaban | 35 | $23,282 |
| RybelsusSemaglutide | 17 | $21,128 |
| FarxigaDapagliflozin Propanediol | 18 | $19,861 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $10,964 |
| Rosuvastatin Calcium | 183 | $10,634 |
| Atorvastatin Calcium | 450 | $9,823 |
| Losartan Potassium | 421 | $9,337 |
| Montelukast Sodium | 210 | $6,395 |
| Amlodipine Besylate | 463 | $5,933 |
| Omeprazole | 228 | $5,515 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $680 | $157,600182 claims |
| Novo NordiskOzempic, Rybelsus | $540 | $75,54969 claims |
| Boehringer IngelheimJardiance | $190 | $46,78731 claims |
| Astellas Pharma US IncMyrbetriq | $185 | $38,38268 claims |
| GSKTrelegy Ellipta | $408 | $31,53946 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $759 | $30,82532 claims |
| Johnson & JohnsonXarelto | $80 | $23,28235 claims |
| AbbVieSynthroid | $542 | $2,17946 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 83 primary care providers in Oklahoma.
Other primary care in Tulsa
- Stephanie PennieTulsa$3K
- Steven OrtmanTulsa$2K
- Ziva CooperTulsa$460
- Linda WilliamsTulsa$399
- Molly BartTulsa$360
- Teri RatzTulsa$300
- Ralynda RozellTulsa$284
- Aimee MusgroveTulsa$235
- Amber MaharSallisaw$9K
- Misty DeanOklahoma City$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.